Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Sashidhar R. Yerram"'
Autor:
Sashidhar R. Yerram, Breann Yanagisawa, Nina Chu, Todd D. Armstrong, Ludmila Danilova, Manuel Hidalgo, Lorraine Pelosof, Nilofer S. Azad, James G. Herman
Publikováno v:
Epigenetics. 12:540-550
Epigenetic control of gene expression is a major determinant of tumor phenotype and has been found to influence sensitivity to individual chemotherapeutic agents. Glutathione peroxidase 3 (GPX3, plasma glutathione peroxidase) is a key component of ce
Autor:
Yue Hu, Rajita Vatapalli, Kevin Wyatt McMahon, Eihab Abdelfatah, Jasvinder A. Singh, Anup Sharma, Angela A. Guzzetta, Stephen B. Baylin, Cynthia A. Zahnow, Nita Ahuja, Sashidhar R. Yerram, Nilofer S. Azad, Zachary Kerner
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0242750 (2020)
[This corrects the article DOI: 10.1371/journal.pone.0176139.].
Autor:
M. Zulfiquer Hossain, Scott E. Kern, Surojit Sur, Carlo Rago, Soma Ghosh, Yunzhao R. Ren, Bogdan C. Paun, Sashidhar R. Yerram, Nilofer A. Azad, Anil K. Bhunia, Christine A. Iacobuzio-Donahue
Publikováno v:
The American Journal of Pathology. 184(1):260-270
Large-magnitude numerical distinctions (>10-fold) among drug responses of genetically contrasting cancers were crucial for guiding the development of some targeted therapies. Similar strategies brought epidemiological clues and prevention goals for g
Autor:
James G. Herman, Calvin Lee, Sashidhar R. Yerram, Megan A. Healey, Nilofer S. Azad, Kalpesh Patel, M. Zulfiquer Hossain, Scott E. Kern, Weijie Poh
Publikováno v:
Oncotarget
// M. Zulfiquer Hossain 1 , Megan A. Healey 1 , Calvin Lee 1 , Weijie Poh 1 , Sashidhar R. Yerram 1 , Kalpesh Patel 1 , Nilofer S. Azad 1 , James G. Herman 1 , and Scott E. Kern 1 1 Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, J
Autor:
Nilofer S. Azad, Rajita Vatapalli, Nita Ahuja, Cynthia A. Zahnow, Stephen B. Baylin, Jasvinder Singh, Sashidhar R. Yerram, Anup Sharma, Eihab Abdelfatah, Angela A. Guzzetta, K. Wyatt McMahon, Yue Hu, Zachary Kerner
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 4, p e0176139 (2017)
PLoS ONE, Vol 12, Iss 4, p e0176139 (2017)
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. In the metastatic setting, the majority of patients respond to initial therapies but eventually develop resistance and progress. In this study, we test the hypo
Publikováno v:
Oncotarget
5-Fluorouracil (5FU) and similar fluoropyrimidines induce covalent modification of thymidylate synthase (TS) and inhibit its activity. They are often used to treat solid cancers, but drug resistance and toxicity are drawbacks. Therefore, there is an
Publikováno v:
Journal of Clinical Oncology. 32:499-499
499 Background: Epigenetic heterogeneity within colorectal and pancreatic tumors influences their sensitivity to individual chemotherapy agents. Glutathione peroxidase 3 (GPX3), part of the cellular antioxidant system, is associated with platinum res
Autor:
Nita Ahuja, A. Delmas, Lorraine Pelosof, Ludmila Danilova, Sashidhar R. Yerram, James G. Herman, Nilofer A. Azad
Publikováno v:
European Journal of Cancer. 49:S33
Publikováno v:
Cancer Research. 73:652-652
An estimated 52,000 people will die from colorectal cancer (CRC) in 2012 in the U.S. Unfortunately, these tumors do not respond uniformly to the available chemotherapeutic agents and molecular heterogeneity in these tumors is an important factor in d
Publikováno v:
Cancer Research. 72:LB-353
Introduction: 5-Fluorouracil (5FU) is a fluorinated nucleoside analogue used in cancer treatment. 5FU metabolites modify thymidylate synthase (TS) to form a ternary complex and inhibit its activity. Despite its benefits, major side effects are common